StockData
Longeveron Inc. logo

Longeveron Inc. (LGVN) stock

LGVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$2.11−0.03 (-1.40%)

Close on Nov 17, 2026Market cap $67.27MP/E –Yield –

Longeveron Inc. saw revenue fall 42.7% to $1.19M over the twelve months to Jun 30, 2026. Free cash flow was -$20.53M. At the latest close the market valued the company at $67.27M.

Revenue
$1.19M
-42.7% vs. a year earlier
Operating income
-$23.66M
TTM Q2 2026
Free cash flow
-$20.53M
TTM Q2 2026
EPS, diluted
-$0.77
TTM Q2 2026

Key statistics

Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026

Valuation

Market cap
$67.27M
P/E ratio
–
Price to sales
56.67
Price to book
6.47
Dividend yield
–
Free cash flow yield
-30.52%

Fundamentals

Revenue
$1.19M
Net income
-$23.47M
EPS, diluted
-$0.77
Free cash flow
-$20.53M
Book value per share
$0.33
Diluted shares
31M

Trading

Previous close
$2.14
Open
$2.23
Day's range
$2.04 – $2.23
Volume
28,298
Average volume (20 days)
100,297
52-week range
$1.31 – $12.30
RSI (14 days)
46.2
Volatility (1 year)
133.4%
Relative volume
0.30×

Market cap history

Month-end market cap since 2021, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.

PeriodLGVNS&P 500DifferenceLGVN per yearS&P 500 per year
1 month+51.8%-4.0%+55.8 pts
3 months-74.3%-5.0%−69.3 pts
Year to date-58.3%+8.2%−66.5 pts
1 year-67.5%+11.2%−78.7 pts
3 years-98.9%+68.5%−167.4 pts-77.7%+19.0%
5 years-99.3%+67.3%−166.6 pts-62.7%+10.8%

Seven years at a glance

Fiscal years 2019 to 2025 and trailing twelve months, USD

Revenue

$1.19M-42.7% YoY

Gross profit

$828.00K-49.3% YoY

Operating income

-$23.66M

Net income

-$23.47M

EPS, diluted

-$0.77

Free cash flow

-$20.53M
Reported periodTrailing twelve months

Press releases

Releases Longeveron filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Longeveron

Pharmaceutical Preparations

Longeveron Inc. is a clinical-stage biotechnology company that develops cellular therapies for unmet medical conditions. Its primary investigational product candidate is laromestrocel, an allogeneic cell therapy designed to promote tissue repair and reduce inflammation. The firm focuses on advancing treatments across several therapeutic indications, including hypoplastic left heart syndrome, Alzheimer’s disease, aging-related frailty, and pediatric dilated cardiomyopathy. Its customer and user base includes clinical trial participants, patients, and third-party partners seeking contract development and manufacturing services.

Company profile, executives and history

Longeveron stock: common questions

What is Longeveron's stock price?

LGVN closed at $2.11 on Nov 17, 2026, down 1.40% on the day. Over the past 52 weeks it traded between $1.31 and $12.30.

What is Longeveron's market cap?

Longeveron was worth $67.27M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.

What is LGVN's P/E ratio?

Longeveron lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.77), so it has no meaningful P/E ratio.

How much revenue does Longeveron make?

Longeveron reported revenue of $1.19M for the twelve months to Jun 30, 2026, down 42.7% from a year earlier.

Does Longeveron pay a dividend?

No. Longeveron has not paid a cash dividend over the last twelve months.

How has LGVN stock performed over the past year?

Including dividends, LGVN returned -67.5% over the past year, against +11.2% for the S&P 500.

How many LGVN shares are sold short?

0M shares were sold short at the latest FINRA report, 0.88% of the float, or 2.2 days of average trading volume.

Who are Longeveron's competitors?

Companies most similar to Longeveron by business, industry and size include IGC, RNAC, MNOV, RFL, NGNE.

See a number that looks wrong?